Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2025)

Heron Therapeutics' Non-Current Debt history spans 5 years, with the latest figure at $107.9 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 331.15% year-over-year to $107.9 million; the TTM value through Dec 2025 reached $107.9 million, up 331.15%, while the annual FY2025 figure was $107.9 million, 331.15% up from the prior year.
  • Non-Current Debt reached $107.9 million in Q4 2025 per HRTX's latest filing, roughly flat from $107.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $107.9 million in Q4 2025 to a low of $24.0 million in Q3 2023.
  • Average Non-Current Debt over 3 years is $43.1 million, with a median of $24.8 million recorded in 2024.
  • The largest YoY upside for Non-Current Debt was 332.93% in 2025 against a maximum downside of 3.13% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024, then soared by 331.15% to $107.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Non-Current Debt are $107.9 million (Q4 2025), $107.5 million (Q3 2025), and $25.2 million (Q1 2025).